Juan Morote

Summary

Affiliation: Hospital Universitari Vall d'Hebron
Country: Spain

Publications

  1. doi request reprint Diagnostic accuracy of prostate health index to identify aggressive prostate cancer. An Institutional validation study
    J Morote
    Departamento de Urologia, Hospital Universitari Vall d Hebron, Barcelona, España Unidad de Investigación en Urología, Instituto de Investigación Vall d Hebron, Barcelona, España Universitat Autònoma de Barcelona, Barcelona, España Electronic address
    Actas Urol Esp 40:378-85. 2016
  2. doi request reprint [Prostate cancer]
    Joan Morote
    Servicio de Urologia, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, España Electronic address
    Med Clin (Barc) 146:121-7. 2016
  3. doi request reprint The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy
    Juan Morote
    Department of Urology, Hospital Vall d Hebron and Universitat Autònoma de Barcelona, Barcelona, Spain Electronic address
    J Urol 193:1963-9. 2015
  4. pmc Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness
    Juan Morote
    Department of Urology, Vall d Hebron University Hospital and Autonomous University of Barcelona, Barcelona 08035, Spain
    Int J Mol Sci 15:13615-23. 2014
  5. doi request reprint Sedentarism and overweight as risk factors for the detection of prostate cancer and its aggressivenes
    J Morote
    Servicio de Urologia, Hospital Vall d́Hebron, Barcelona, España Departamento de Cirugía, Universitat Autonoma de Barcelona, Barcelona, España Electronic address
    Actas Urol Esp 38:232-7. 2014
  6. doi request reprint Metabolic syndrome in patients with prostate cancer undergoing androgen suppression
    J Morote
    Servicio de Urologia, Hospital Vall d́Hebron, Universitat Autonoma de Barcelona, Barcelona, España Electronic address
    Actas Urol Esp 38:285-9. 2014
  7. doi request reprint Metabolic syndrome increases the risk of aggressive prostate cancer detection
    Juan Morote
    Department of Urology, Universitat Autonoma de Barcelona, Paseo Vall d Hebron 119 129, Barcelona, Spain
    BJU Int 111:1031-6. 2013
  8. pmc Identification, characterization and expression of novel Sex Hormone Binding Globulin alternative first exons in the human prostate
    Tomàs Pinós
    Institut de Recerca Hospital Universitari Vall d Hebron, Barcelona, Spain
    BMC Mol Biol 10:59. 2009
  9. ncbi request reprint Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression
    Juan Morote
    Department of Urology, Vall d Hebron Hospital, Autonoma University School of Medicine, Barcelona, Spain
    J Urol 175:1679-83; discussion 1683. 2006
  10. doi request reprint Improved prediction of biochemical recurrence after radical prostatectomy by genetic polymorphisms
    Juan Morote
    Hospital Universitario Vall d Hebron, Barcelona, Spain
    J Urol 184:506-11. 2010

Collaborators

Detail Information

Publications69

  1. doi request reprint Diagnostic accuracy of prostate health index to identify aggressive prostate cancer. An Institutional validation study
    J Morote
    Departamento de Urologia, Hospital Universitari Vall d Hebron, Barcelona, España Unidad de Investigación en Urología, Instituto de Investigación Vall d Hebron, Barcelona, España Universitat Autònoma de Barcelona, Barcelona, España Electronic address
    Actas Urol Esp 40:378-85. 2016
    ..The objective of this study has been to validate Prostate Health Index (PHI) as a marker of aggressive PCa in one academic institution...
  2. doi request reprint [Prostate cancer]
    Joan Morote
    Servicio de Urologia, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, España Electronic address
    Med Clin (Barc) 146:121-7. 2016
    ..After castration resistance in metastatic disease, new hormone-based drugs have demonstrated efficacy even after chemotherapy resistance. ..
  3. doi request reprint The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy
    Juan Morote
    Department of Urology, Hospital Vall d Hebron and Universitat Autònoma de Barcelona, Barcelona, Spain Electronic address
    J Urol 193:1963-9. 2015
    ..We assessed the prevalence of the full metabolic syndrome and its components during the first year of androgen deprivation therapy...
  4. pmc Role of serum cholesterol and statin use in the risk of prostate cancer detection and tumor aggressiveness
    Juan Morote
    Department of Urology, Vall d Hebron University Hospital and Autonomous University of Barcelona, Barcelona 08035, Spain
    Int J Mol Sci 15:13615-23. 2014
    ..23-0.44), while statin usage could not. Statin treatment may prevent PCa detection through serum cholesterol-mediated mechanisms. A disturbing increase in the HGPCa rate was observed in statin users who normalized their serum cholesterol...
  5. doi request reprint Sedentarism and overweight as risk factors for the detection of prostate cancer and its aggressivenes
    J Morote
    Servicio de Urologia, Hospital Vall d́Hebron, Barcelona, España Departamento de Cirugía, Universitat Autonoma de Barcelona, Barcelona, España Electronic address
    Actas Urol Esp 38:232-7. 2014
    ..To analyze the influence of sedentary (SE) and overweight (OW) in the risk of prostate cancer detection (CP) and aggressiveness...
  6. doi request reprint Metabolic syndrome in patients with prostate cancer undergoing androgen suppression
    J Morote
    Servicio de Urologia, Hospital Vall d́Hebron, Universitat Autonoma de Barcelona, Barcelona, España Electronic address
    Actas Urol Esp 38:285-9. 2014
    ..The main objective of this study was to determine the prevalence of MS in patients with CP undergoing androgen suppression (AS)...
  7. doi request reprint Metabolic syndrome increases the risk of aggressive prostate cancer detection
    Juan Morote
    Department of Urology, Universitat Autonoma de Barcelona, Paseo Vall d Hebron 119 129, Barcelona, Spain
    BJU Int 111:1031-6. 2013
    ..This study indicates that tumours detected in men with metabolic syndrome are more aggressive than those detected in men without this condition...
  8. pmc Identification, characterization and expression of novel Sex Hormone Binding Globulin alternative first exons in the human prostate
    Tomàs Pinós
    Institut de Recerca Hospital Universitari Vall d Hebron, Barcelona, Spain
    BMC Mol Biol 10:59. 2009
    ..Our goal has been to further characterize the 5' end of the SHBG gene and analyze the presence of the SHBG alternative transcripts in human prostate tissue and derived cell lines...
  9. ncbi request reprint Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression
    Juan Morote
    Department of Urology, Vall d Hebron Hospital, Autonoma University School of Medicine, Barcelona, Spain
    J Urol 175:1679-83; discussion 1683. 2006
    ..We characterized bone mineral density changes in patients with prostate cancer on androgen deprivation therapy during the first 2 years of uninterrupted therapy, and identified which location most reflects bone mass loss...
  10. doi request reprint Improved prediction of biochemical recurrence after radical prostatectomy by genetic polymorphisms
    Juan Morote
    Hospital Universitario Vall d Hebron, Barcelona, Spain
    J Urol 184:506-11. 2010
    ..We hypothesized that single nucleotide polymorphism profiling may improve the prediction of biochemical recurrence after radical prostatectomy...
  11. doi request reprint Behavior of the PCA3 gene in the urine of men with high grade prostatic intraepithelial neoplasia
    Juan Morote
    Department of Urology, Vall d Hebron University Hospital, Pg Vall d Hebron 119 129, 08035, Barcelona, Spain
    World J Urol 28:677-80. 2010
    ..Because PCA3 is also expressed in the HGPIN lesion, the aim of this study was to determine the efficacy of PMU-PCA3 scores for ruling out PCa in men with previous HGPIN...
  12. ncbi request reprint Behavior of free testosterone in patients with prostate cancer on androgen deprivation therapy
    J Morote
    Department of Urology, Vall d Hebron University Hospital, Barcelona, Spain
    Int J Biol Markers 20:119-22. 2005
    ..We also analyzed the efficiency of both isoforms in the evaluation of the ADT...
  13. doi request reprint [Loss of bone mass in patients with prostate cancer subjected to androgenic deprivation]
    J Morote
    Servicio de Urologia, Hospital Vall d Hebron, Universidad Autonoma de Barcelona, Espana
    Actas Urol Esp 35:232-9. 2011
    ..Moreover, its use is increasing due to a clear expansion of the indications of this therapy in patients with localized cancer...
  14. doi request reprint Evaluation of the serum testosterone to prostate-specific antigen ratio as a predictor of prostate cancer risk
    Juan Morote
    Department of Urology, Vall d Hebron Hospital, Autonoma University of Barcelona, Spain
    BJU Int 105:481-4. 2010
    ....
  15. ncbi request reprint Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer
    Juan Morote
    Urology Department, Vall d Hebron Hospital, Autonoma University of Barcelona, Po Vall d Hebron 119 129, 08035 Barcelona, Spain
    Int J Cancer 108:877-81. 2004
    ....
  16. doi request reprint 33% radius evaluation to assess bone mineral density in prostate cancer patients
    Juan Morote
    Department of Urology, Vall d Hebron Hospital, Autónoma University Medical School of Barcelona, Po Vall d Hebron, 119 129, 08035, Barcelona, Spain
    World J Urol 29:815-9. 2011
    ..The aim of this study has been to analyze whether 33% radius should be considered the recommended area to assess BMD in prostate cancer patients...
  17. doi request reprint The relationship between total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness
    Juan Morote
    Translational Prostate Cancer Research Program, Vall d Hebron Hospital, Autonoma University, Medical School, Barcelona, Spain
    BJU Int 104:486-9. 2009
    ..To analyse the relationship between the levels of total and free serum testosterone and the risk of prostate cancer and tumour aggressiveness...
  18. doi request reprint Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy
    Juan Morote
    Department of Urology, Vall d Hebron Hospital, Autonoma University of Barcelona, Barcelona, Spain
    BJU Int 103:332-5; discussion 335. 2009
    ..To analyse individual variations in serum testosterone level, the cumulative rate of 'breakthrough' increases over castrate levels, and to evaluate whether the increases can be predicted...
  19. ncbi request reprint Effect of androgen deprivation therapy in the thyroid function test of patients with prostate cancer
    Juan Morote
    Departments of Urology, Vall d Hebron Hospital, Autonoma University of Barcelona, Barcelona, Spain
    Anticancer Drugs 16:863-6. 2005
    ..However, only a mild hypothyroidism was detected in about 2% of the patients with prostate cancer, independently of ADT...
  20. ncbi request reprint Usefulness of prostate-specific antigen nadir as predictor of androgen-independent progression of metastatic prostate cancer
    J Morote
    Department of Urology, Vail d Hebron University Hospital, Barcelona, Spain
    Int J Biol Markers 20:209-16. 2005
    ..Time to PSA nadir, extent of bone involvement and Gleason score are also independent predictors. The combination of these prognostic factors allows to stratify metastatic prostate cancer patients for the prediction of AIP...
  21. ncbi request reprint Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy
    Juan Morote
    Department of Urology, Vall d Hebron Hospital and Autonoma University of Barcelona School of Medicine, Barcelona, Spain
    J Urol 178:1290-5. 2007
    ..Secondary objectives were to analyze the role of associated bicalutamide in breakthrough increases of serum testosterone in these patients and the possible benefit of maximal androgen blockade...
  22. ncbi request reprint Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer
    Juan Morote
    Department of Urology, Vall d Hebron Hospital, Autonoma University School of Medicine, Barcelona, Spain
    Urology 69:500-4. 2007
    ..To know the prevalence of osteoporosis in patients with prostate cancer according to the duration of androgen deprivation therapy (ADT)...
  23. ncbi request reprint Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer
    Juan Morote
    Department of Urology, Vall d Hebron University Hospital, Barcelona, Spain
    Urol Int 77:135-8. 2006
    ....
  24. doi request reprint Genetic predisposition to early recurrence in clinically localized prostate cancer
    Angel Borque
    Department of Urology, Miguel Servet University Hospital, P Isabel la Catolica 1 y 3, 50 009 Zaragoza, Spain
    BJU Int 111:549-58. 2013
    ..The new nomogram, which combines clinicopathological and genetic variables, will help to improve prediction of prostate cancer recurrence...
  25. doi request reprint Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis
    Jacques Planas
    Department of Urology, Hospital Vall d Hebron, Barcelona, Spain
    BJU Int 104:1637-40. 2009
    ..0, who were treated with an oral bisphosphonate, as such patients treated with ADT are at increased risk of bone loss and bone fracture...
  26. ncbi request reprint The relationship between daily calcium intake and bone mineral density in men with prostate cancer
    Jacques Planas
    Department of Urology Vall d Hebron Hospital, Autonoma University School of Medicine, Barcelona, Spain
    BJU Int 99:812-5; discussion 815-6. 2007
    ..To analyse the relationship between daily calcium intake (DCI) and bone mineral density (BMD) in patients with prostate cancer, and to assess if DCI is a risk factor for osteoporosis in this group of patients...
  27. doi request reprint Is there a relationship between prostate volume and Gleason score?
    Maria Carmen Mir
    Department of Urology, Vall d Hebron Hospital, Autonoma University School of Medicine, Barcelona, Spain
    BJU Int 102:563-5. 2008
    ..To review the relationship between the Gleason grade and prostate volume in biopsy and radical prostatectomy (RP) specimens, and thus assess the hypothesis that smaller prostates have a greater incidence of high-grade tumours...
  28. pmc Molecular markers for prostate cancer in formalin-fixed paraffin-embedded tissues
    Tamara Sequeiros
    Research Unit in Biomedicine and Translational Oncology, Research Institute Vall Hebron University Hospital VHIR and Universitat Autònoma de Barcelona UAB, 08035 Barcelona, Spain
    Biomed Res Int 2013:283635. 2013
    ..In this review, we attempt to summarize and discuss the potential use of microRNA and protein profiles in FFPE tissue samples as markers to better predict PCa diagnosis, progression, and response to therapy. ..
  29. doi request reprint PTOV1 expression predicts prostate cancer in men with isolated high-grade prostatic intraepithelial neoplasia in needle biopsy
    Juan Morote
    Department of Urology, Vall d Hebron Hospital, Vall d Hebron Hospital Research Institute, and Autónoma University of Barcelona, Barcelona, Spain
    Clin Cancer Res 14:2617-22. 2008
    ..To analyze the expression of PTOV1 in high-grade prostatic intraepithelial neoplasia (HG-PIN) and to explore its usefulness to predict prostate cancer in patients with isolated HG-PIN in needle biopsy (prostate needle biopsy)...
  30. doi request reprint PTOV1 is overexpressed in human high-grade malignant tumors
    Sara Fernandez
    Department of Pathology, Vall Hebron Hospital, Barcelona, Spain
    Virchows Arch 458:323-30. 2011
    ..005). In conclusion, PTOV1 expression is associated to more aggressive human carcinomas and more significantly to bladder carcinomas suggesting that this protein is a potential new marker of aggressive disease in the latter tumors...
  31. pmc PTOV1 enables the nuclear translocation and mitogenic activity of flotillin-1, a major protein of lipid rafts
    Anna Santamaria
    Unitat de Recerca Biomedica, Hospital Vall d Hebron, Passeig Vall d Hebron 119 129, 00835 Barcelona, Spain
    Mol Cell Biol 25:1900-11. 2005
    ..These observations suggest that PTOV1 assists flotillin-1 in its translocation to the nucleus and that both proteins are required for cell proliferation...
  32. doi request reprint PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine
    Marina Rigau
    Biomedical Research Unit, Research Institute, Vall d Hebron UniversityHospital, Barcelona, Spain
    Prostate 70:1760-7. 2010
    ..PCa screening would benefit from additional biomarkers of higher specificity and could be used in conjunction with prostate-specific antigen (PSA) testing, in order to better determine biopsy candidates...
  33. ncbi request reprint Effect of chronic treatment of combined statins and aspirin on the risk of prostate cancer detection
    Cristina Suarez
    Oncology Department, Vall d Hebron University Hospital, Barcelona, Spain Passeig Vall Hebron 119 129, Barcelona, Spain Vall d Hebron University Hospital, Barcelona, Spain Urology Department, Vall d Hebron University Hospital, Barcelona, Spain
    J Clin Oncol 30:185. 2012
    ..The impact of the combined treatment (CT) with statins and aspirin on PC risk has never been reported. We proposed to explore the influence of ChT with statins and aspirin in the PC risk detection and their aggressiveness...
  34. ncbi request reprint The percentage of free prostatic-specific antigen is also useful in men with normal digital rectal examination and serum prostatic-specific antigen between 10.1 and 20 ng/ml
    Juan Morote
    Department of Urology, Vall d Hebron Hospital, Po Vall d Hebron 119 129, Autonoma University of Barcelona, Barcelona 0835, Spain
    Eur Urol 42:333-7. 2002
    ..1 and 10 ng/ml. In this series we also analyze its utility in men with normal DRE and serum PSA between 10.1 and 20 ng/ml...
  35. pmc The present and future of prostate cancer urine biomarkers
    Marina Rigau
    Research Unit in Biomedicine and Translational Oncology, Vall d Hebron Research Institute and Hospital and Autonomous University of Barcelona, 08035 Barcelona, Spain
    Int J Mol Sci 14:12620-49. 2013
    ..Herein, we will review the most significant urine biomarkers described in recent years, as well as some future prospects in that field...
  36. doi request reprint Risk factors for positive findings in patients with high-grade T1 bladder cancer treated with transurethral resection of bladder tumour (TUR) and bacille Calmette-Guérin therapy and the decision for a repeat TUR
    Anna Orsola
    Department of Urology, Hospital Vall d Hebron, Barcelona, Spain
    BJU Int 105:202-7. 2010
    ....
  37. doi request reprint A three-gene panel on urine increases PSA specificity in the detection of prostate cancer
    Marina Rigau
    Research Unit in Biomedicine and Translational and Pediatric Oncology, Vall d Hebron Research Institute, Barcelona, Spain
    Prostate 71:1736-45. 2011
    ..However, a single marker may not necessarily reflect the multifactorial nature of PCa...
  38. doi request reprint Expert opinion on first-line therapy in the treatment of castration-resistant prostate cancer
    Pablo Maroto
    Department of Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain Electronic address
    Crit Rev Oncol Hematol 100:127-36. 2016
    ..Finally, the panel discuss how to define progressive disease in the setting of mCRPC and treatment with targeted therapies...
  39. doi request reprint Targeting fibroblast growth factor receptors and immune checkpoint inhibitors for the treatment of advanced bladder cancer: New direction and New Hope
    Rafael Morales-Barrera
    Vall d Hebron Institute of Oncology, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Cancer Treat Rev 50:208-216. 2016
    ....
  40. ncbi request reprint The influence of metabolic syndrome on prostate cancer risk detection and its aggressiveness
    Rafael Morales
    Oncology Department, Vall d Hebron University Hospital, Barcelona, Spain Urology Department, Vall d Hebron University Hospital, Barcelona, Spain Vall d Hebron University Hospital, Barcelona, Spain Passeig Vall Hebron 119 129, Barcelona, Spain
    J Clin Oncol 30:226. 2012
    ..Some studies have postulated a relationship between MS and overall oncogenesis, however no information exist in relation to PC. The objective of this study was to analyze the impact of MS on PC detection risk and PC aggressiveness...
  41. ncbi request reprint Effect of denosumab on prolonging bone-metastasis-free survival (BMFS) in men with nonmetastatic castrate-resistant prostate cancer (CRPC) presenting with aggressive PSA kinetics
    Matthew R Smith
    Massachusetts General Hospital Cancer Center, Boston, MA University of Montreal Hospital Center, Montreal, QC, Canada Carolina Urologic Research Center, Myrtle Beach, SC Georges Pompidou European Hospital, Paris, France Department of Urology, Charite Universitatsmedizin, Berlin, Germany Université Catholique de Louvain, Cliniques Universitaires Saint Luc, Brussels, Belgium Urological Associates of Lancaster, Ltd, Lancaster, PA Institut Gustave Roussy, University of Paris Sud, Villejuif, France Kansas City VA Medical Center, Kansas City, MO Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil Sydney Haematology Oncology Clinics, Sydney, Australia Urology Department, Vall d Hebron University Hospital, Barcelona, Spain Amgen Inc, Thousand Oaks, CA
    J Clin Oncol 30:6. 2012
    ..To determine the efficacy of denosumab in men at greatest risk for bone metastases, we evaluated BMFS in a subset of men with PSADT < 6 months, a cutoff based on a previous report (Smith MR, et al: J Clin Oncol. 23:2918-2925, 2005)...
  42. ncbi request reprint Hormonal response recovery after long-term androgen deprivation therapy in patients with prostate cancer
    Jacques Planas
    A Urology Department, Hospital Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    Scand J Urol 50:425-428. 2016
    ..The aim of this study was to evaluate hormonal recovery after cessation of androgen deprivation therapy (ADT) in a group of elderly prostate cancer patients...
  43. doi request reprint Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice
    Marta Garcia
    Research Unit in Biomedicine and Translational and Pediatric Oncology, Research Institute Vall d Hebron University Hospital VHIR, Barcelona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain
    BJU Int 113:E164-77. 2014
    ..To assess whether celecoxib, a selective cyclooxygenase-2 (COX-2) inhibitor with anti-cancer properties, has an inhibitory effect on tumour establishment and progression of prostate cancer (PCa) bone metastases...
  44. doi request reprint Identification of somatic gene mutations in penile squamous cell carcinoma
    Carla Ferrándiz-Pulido
    Dermatology Department, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Genes Chromosomes Cancer 54:629-37. 2015
    ..Although the presence of these mutations does not seem to correlate with tumoral behavior or outcome, they could be biomarkers of treatment failure with anti-EGFR mAb in patients with penile squamous cell carcinoma...
  45. doi request reprint Urinary biomarkers for the detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia
    Tamara Sequeiros
    Group of Biomedical Research in Urology, Vall d Hebron Research Institute VHIR and Universitat Autònoma de Barcelona UAB, Barcelona, Spain
    Prostate 75:1102-13. 2015
    ..This study aimed to identify non-invasive prognostic biomarkers that differentiate early on between indolent HGPIN cases and those that will transform into actual PCa...
  46. doi request reprint HAVCR/KIM-1 activates the IL-6/STAT-3 pathway in clear cell renal cell carcinoma and determines tumor progression and patient outcome
    Thaïs Cuadros
    Authors Affiliations Fisiopatología Renal, CIBBIM Statistics and Bioinformatics Unit UEB, Vall d Hebron Institute of Research Servicio de Urología, Hospital Vall d Hebron Servicio de Anatomía Patológica, Hospital Vall d Hebrón Departament de Bioquímica i Biologia Molecular, Unitat de Bioquimica, Facultat de Biociències Departament de Bioquimica i Biologia Molecular, Unitat de Bioquímica de Medicina, Universitat Autonoma de Barcelona, Bellaterra and Instituto Reina Sofía de Investigación Nefrológica, Fundación Renal Iñigo Alvarez de Toledo, Spain
    Cancer Res 74:1416-28. 2014
    ..Our results suggest that HAVCR/KIM-1 upregulation in tumors might represent a novel mechanism to activate tumor growth and angiogenesis and that pSTAT-3 S727 is an independent prognostic factor for ccRCC...
  47. ncbi request reprint [Usefulness of prostatic specific antigen (PSA) for diagnosis and staging of patients with prostate cancer]
    Jose Placer
    Servicio de Urologia, Hospital Universitario Vall d Hebron, Universitat Autonoma de Barcelona, Espana
    Arch Esp Urol 64:659-80. 2011
    ..With the ongoing development of new markers for PCa, It is likely the role of PSA in diagnosis and staging of the disease will be modified...
  48. doi request reprint Altered transcription factor E3 expression in unclassified adult renal cell carcinoma indicates adverse pathological features and poor outcome
    Maria Carmen Mir
    Vall d Hebron Hospital Urology Department, Barcelona, Spain
    BJU Int 108:E71-6. 2011
    ..Recent studies suggest that renal cell carcinomas (RCCs) associated with the newly recognized Xp11.2 translocation (transcription factor E3 [TFE3] gene fusions) can be found among adults with RCC showing a very aggressive disease-course...
  49. ncbi request reprint [Epidemiology of urinary incontinence in prostate cancer. Incidence, quality of life and farmacoeconomic features]
    Anna Orsola
    Servicio de Urologia, Hospital Vall d Hebron, 08035 Barcelona, Espana
    Arch Esp Urol 62:786-92. 2009
    ..To present recent data on the epidemiology of urinary incontinence in prostate cancer (PCa). To review the incidence of urinary incontinence, its impact on quality of life and related pharmacoeconomic features...
  50. doi request reprint Clinical Significance of Proliferative Inflammatory Atrophy in Negative Prostatic Biopsies
    Pol Servian
    Department of Urology, Vall d Hebron Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Prostate 76:1501-1506. 2016
    ....
  51. doi request reprint Clinical significance of proliferative inflammatory atrophy finding in prostatic biopsies
    Pol Servian
    Departments of Urology, Barcelona, Spain
    Prostate 75:1669-75. 2015
    ....
  52. doi request reprint Effects of holmium laser enucleation of the prostate on sexual function
    Jose Placer
    Department of Urology, Hospital Vall d Hebron, Barcelona, Spain and Universitat Autonoma de Barcelona, Barcelona, Spain
    J Endourol 29:332-9. 2015
    ..To evaluate the effects of holmium laser enucleation of the prostate (HoLEP) on sexual function...
  53. ncbi request reprint Case report: retroperitoneal fibrosis simulating local relapse of sarcomatoid renal cell carcinoma
    Salvador Esquena
    Department of Urology and Pathology, Hospital Universitari Vall d Hebron, Po Vall d Hebron 119 129, 08035, Barcelona, Spain
    Int Urol Nephrol 38:463-5. 2006
    ..CT scan is the best choice for diagnosis. Other aetiologies described are malignancies, drugs, aorta aneurisms and immunological or rheumatological diseases...
  54. ncbi request reprint [Holmium laser enucleation of the prostatic adenoma]
    Jose Placer
    Servei d Urologia, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Espana
    Arch Esp Urol 64:246-56. 2011
    ..In this article we describe in detail the technique we use in our center for the performance of HoLEP, emphasizing the modifications we have introduced with time to make the operation easier and to avoid complications...
  55. doi request reprint Free Testosterone During Androgen Deprivation Therapy Predicts Castration-Resistant Progression Better Than Total Testosterone
    Lucas Regis
    Department of Urology, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain
    Prostate 77:114-120. 2017
    ..Here we compared free and total serum testosterone as predictors of survival free of castration resistance...
  56. doi request reprint Targeted proteomics in urinary extracellular vesicles identifies biomarkers for diagnosis and prognosis of prostate cancer
    Tamara Sequeiros
    Group of Biomedical Research in Urology, Vall d Hebron Research Institute VHIR and Universitat Autònoma de Barcelona UAB, Barcelona, Spain
    Oncotarget . 2016
    ....
  57. doi request reprint Role of immunotherapy in castration-resistant prostate cancer (CRPC)
    Cristina Suarez
    Genitourinary, Sarcoma, and Central Nervous System Tumor Program, Medical Oncology Department, Universitat Autonoma Barcelona, Barcelona, Spain
    BJU Int 113:367-75. 2014
    ..Here we provide a review of the main important immune treatments in CRPC. ..
  58. doi request reprint Identification and genotyping of human papillomavirus in a Spanish cohort of penile squamous cell carcinomas: correlation with pathologic subtypes, p16(INK4a) expression, and prognosis
    Carla Ferrándiz-Pulido
    Department of Dermatology, Hospital Universitari Vall d Hebron, Barcelona, Spain
    J Am Acad Dermatol 68:73-82. 2013
    ..Penile squamous cell carcinoma (PSCC) is a tumor with a high metastatic potential. In PSCC the attributable fraction to human papillomavirus (HPV) is not well established...
  59. pmc PTOV-1, a novel protein overexpressed in prostate cancer, shuttles between the cytoplasm and the nucleus and promotes entry into the S phase of the cell division cycle
    Anna Santamaria
    Unitat de Recerca Biomedica, Hospital Vall d Hebron, Barcelona, Spain
    Am J Pathol 162:897-905. 2003
    ..These observations suggest that overexpression of PTOV1 can contribute to the proliferative status of prostate tumor cells and thus to their biological behavior...
  60. ncbi request reprint [Prostate cancer. New diagnostic techniques. Current status of prostate biopsy]
    Enrique Trilla
    Servicio de Urologia, Hospital Vall d Hebron, Universidad Autonoma de Barcelona, Barcelona, Espana
    Arch Esp Urol 59:945-52. 2006
    ....
  61. pmc Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time
    Matthew R Smith
    Matthew R Smith, Massachusetts General Hospital Cancer Center, Boston, MA Fred Saad, University of Montreal Hospital Center, Montreal, Quebec, Canada Stephane Oudard, Georges Pompidou Hospital, Paris Karim Fizazi, Institut Gustave Roussy, University of Paris Sud, Villejuif, France Neal Shore, Carolina Urological Research Center, Myrtle Beach, SC Paul Sieber, Urological Associates of Lancaster, Lancaster, PA Bertrand Tombal, Université Catholique de Louvain Cliniques Universitaires Saint Luc, Bruxelles, Belgium Ronaldo Damiao, Hospital Universitario Pedro Ernesto, Rio de Janeiro, Brazil Gavin Marx, Sydney Haematology and Oncology Clinic, University of Sydney, Wahroonga, New South Wales, Australia Kurt Miller, Charite Berlin, Berlin, Germany Peter Van Veldhuizen, Kansas City Veterans Affairs Medical Center, Kansas City, MO Juan Morote, Hospital Vall d Hebron, Barcelona, Saudi Arabia
    J Clin Oncol 31:3800-6. 2013
    ..To identify men at greatest risk for bone metastasis or death, we evaluated relationships between PSA and PSADT with BMFS in the placebo group and the efficacy and safety of denosumab in men with PSADT ≤ 10, ≤ 6, and ≤ 4 months...
  62. ncbi request reprint [Biochemical recurrence criteria after radical prostatectomy. Natural history of the disease]
    Jacques Planas
    Programa de Investigación Traslacional en Cáncer de Próstata, Servicio de Urologia, Instituto de Investigación Biomédica, Hospital Universitario Vall d Hebron, Universidad Autonoma de Barcelona, Espana
    Arch Esp Urol 65:4-11. 2012
    ..To analyze biochemical recurrence criteria, attending to different PSA-cut-points referred in the literature, and to review prostate cancer natural history...
  63. ncbi request reprint Increase of bone alkaline phosphatase after androgen deprivation therapy in patients with prostate cancer
    Juan Morote
    Department of Urology, Vall d Hebron Hospital and Autónoma University School of Medicine, Barcelona, Spain
    Urology 59:277-80. 2002
    ..To evaluate the behavior of bone alkaline phosphatase (BAP) after androgen deprivation therapy in patients with prostate cancer...
  64. ncbi request reprint Gastric cancer in augmentation gastrocystoplasty
    Salvador Esquena Fernández
    Department of Urology, Hospital Universitari Vall d Hebron, Barcelona, Spain
    Urol Int 74:368-70. 2005
    ..Urologists should be aware of this potential degeneration, and long-term follow-up is mandatory to detect malignization of these cystoplasties...
  65. doi request reprint Antiproliferative and apoptotic effects of the herbal agent Pygeum africanum on cultured prostate stromal cells from patients with benign prostatic hyperplasia (BPH)
    Maria T Quiles
    Institut de Recerca, Hospital Universitari Vall d Hebron, Universitat Autonoma de Barcelona, Barcelona, Spain
    Prostate 70:1044-53. 2010
    ..An interaction of PA with growth factors and hormones was also investigated...
  66. ncbi request reprint [Bone mineral density evaluation: a new tool for the urologist]
    Planas Jacques
    Servicio de Urologia, Hospital Vail d Hebron, Universidad Autonoma, Barcelona, Espana
    Arch Esp Urol 59:1031-40. 2006
    ..To familiarize the urologist with the various diagnostic tests currently available for bone mineral density measurement, as well as to perform an update on bone mineral densitometry...
  67. doi request reprint Variant forms of bladder cancer: basic considerations on treatment approaches
    Francesc Pons
    Medical Oncology Service, University Hospital del Mar, Barcelona, Spain
    Curr Oncol Rep 13:216-21. 2011
    ..In the present report, existent literature about variant forms of bladder cancer is reviewed with focus on the most frequent: squamous cell, adenocarcinoma, small cell, micropapillary, sarcomatoid, and lymphoepithelioma-like...
  68. pmc Bladder cancer in an inguinoscrotal vesical hernia
    Lucas Regis
    Servicio de Urologia, Hospital General Universitario Vall d Hebron, Pg De la Vall d Hebron 119 129, 08035 Barcelona, Spain
    Case Rep Oncol Med 2012:142351. 2012
    ..The presence of bladder tumor in an inguinoscrotal hernia is an uncommon finding and a diagnostic delay can be assumed. The initial therapeutic plan may need to be changed from the usual approaches due to the atypical presentation...
  69. doi request reprint Prostate cancer in Spain: from guidelines to clinical practice
    Antonio Alcaraz
    Hospital Clinic, IDIBAPS, Barcelona, Madrid, Spain
    BJU Int 108:61-6. 2011
    ..To determine how closely practice in prostate cancer (PCa) follows European Association of Urology (EAU) guidelines...